NCT06499857View on ClinicalTrials.gov

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 14, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Overweight or ObesityAtrial Fibrillation
Interventions
DRUG

Semaglutide

3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.

DRUG

Placebo

3ml pen-injector containing placebo solution for subcutaneous use.

Trial Locations (2)

60637

RECRUITING

University of Chicago, Chicago

85004

NOT_YET_RECRUITING

The University of Arizona College of Medicine- Phoenix, Phoenix

All Listed Sponsors
lead

University of Chicago

OTHER